Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Lasmiditan in Acute Migraine
NCT04218162Phase 3Completed
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Mar 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lasmiditan in migraine (3 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoint: Percentage of Participants Headache Pain Free at 2 Hours Post Dose. Started Mar 2020; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04218162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218162.